Our experience
Our biotechnology practice is defined by its diversity and adaptability. We work with clients ranging from early-stage spin-outs to multinational corporations, tailoring our approach to suit each organisation’s goals and technology landscape.
We have supported developers of RNA-based therapeutics and delivery platforms, companies advancing synthetic biology and engineered cell systems, academic institutions commercialising molecular diagnostics and bioinformatics tools, biotech firms focused on rare disease treatments and regenerative medicine, and cross-disciplinary teams working on machine-enabled RNA printing and lipid nanoparticle delivery systems.
Our team is frequently called upon to advise on multi-technology patent portfolios that span chemistry, electronics, and life sciences. We understand the nuances of protecting biotech inventions that intersect with AI, automation, and data-driven platforms.
Our expertise
Our attorneys combine scientific depth with commercial insight to support innovation across molecular biology, bioinformatics, and synthetic biology.
Our biotechnology team includes patent attorneys with advanced degrees in immunology, oncology, biochemistry, proteomics, and microbiology. We have particular expertise in chimeric molecules for therapeutic and diagnostic use, modified nucleic acid technologies and gene expression control, lipid nanoparticle delivery systems, RNA printing technologies, genetically modified plants and animals, and bioinformatics platforms and computational biology.
Our attorneys are actively involved in drafting and prosecuting UK and European patent applications in these areas, and regularly advise on patent strategy for emerging biotech platforms. We also support clients with freedom-to-operate analyses, SPCs, and regulatory data exclusivity matters.
For further information please contact:
